(logistic regression model), and overnight global rating (proportional odds model). Results: Statistical power in the Hp pos group was low due to small numbers of subjects (Table) . O was significantly better than P in Hp pos (pϽ0.05) but not in the larger Hp neg. Results for all 3 measures were 18 -31% better in the Hp pos group. R was significantly better than P in Hp neg (pϽ0.05) but not in the Hp pos, although the responses with R were numerically similar between groups. Significantly more Hp neg subjects taking R experienced no nighttime HB symptoms than did O-treated subjects (pϽ0.05). Rescue use and overnight global rating were significantly better for R but not O vs. P in Hp neg, and significantly better for O but not R vs. P in Hp pos (pϽ0.05). Purpose: Previously, we determined the extent to which integrated gastric acidity needs to be decreased to prevent pathologic esophageal reflux in GERD subjects treated with a proton pump inhibitor. Such an assessment is probably not practical for most clinical gastroenterologists. In the present study we determined whether fasting gastric pH can predict the likelihood of pathological esophageal reflux in GERD subjects treated with a proton pump inhibitor. Methods: Analyses were based on 24-hour recordings of esophageal and gastric pH from 26 healthy control subjects and 57 subjects with GERD who experienced heartburn at least 4 times/week for at least 6 months. In 27 of the GERD subjects, pH was also recorded on days 1, 2 and 8 of treatment with 20mg omeprazole and 20mg rabeprazole in a randomized, 2-way crossover fashion. Results: Using receiver operating characteristic analysis, the value for integrated esophageal acidity that gave optimal discrimination between normal and pathologic esophageal reflux was 8.1mmol.hr/L. We used this value to examine the ability of fasting gastric pH to predict pathologic esophageal reflux. The optimal value for fasting gastric pH that distinguished between GERD subjects with and without pathologic reflux was 1.38. This value had a sensitivity of 84% and a specificity of 54% for pathologic esophageal reflux. We also calculated the probability of pathologic esophageal reflux for each value of gastric pH and found that the probability of pathologic esophageal reflux could be related to gastric pH by an equation with a single exponential function. This equation fit the data with R 2 of 0.99. With fasting gastric pH Ͻ0.7, the calculated probability of pathologic reflux was 36%, and with gastric pH Ͼ3.3, the probability was 0%. There was close agreement between predicted and observed percentages of subjects with pathologic esophageal reflux during different days of treatment. For example, after 1 day of treatment, the predicted percentage of subjects with pathologic reflux was 16.2% [12.5, 19.9] (mean, 95% CI) and the observed percentage was 19.0% [3.9, 34.1].
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Conclusions:
The present results indicate that in GERD subjects treated with a proton pump inhibitor, measuring fasting gastric pH is a simple, convenient method to predict the likelihood of pathologic esophageal reflux. This method has a high degree of precision and can be used to optimize treatment of GERD. Wasim Jafri, F.R.C.P., FACG*, Javed Yakoob, Ph.D., Nadim Jafri, F.C.P.S., Shahab Abid, F.C.P.S., Hasnain AliShah, F.R.C.P., FACG, Saeed Hamid, F.R.C.P., FACG, Akbar S. Hussainy, F.C.P.S. Aga Khan University Hospital, Stadium Road, Karachi, Sindh, Pakistan. Purpose: Candida esophagitis is a frequent infection in immunocompromised patients. This study was designed to determine its characteristics in patients attending a teaching hospital. Methods: Methods Clinical records of patients ICD-9-CM coded with candida esophagitis diagnosed by EGD and histopathology over a period of 5 years were studied. Clinical symptoms on presentation, past history of oral candidiasis, candida esophagitis, drug treatment dosage and duration preceding the symptoms particularly antibiotics, corticosteroids, etc were noted. The laboratory investigations including complete blood picture, random blood glucose, hepatitis B, C and HIV serology were also noted. Candida esophagitis was graded as grade 1, scattered mucosal plaques, involving less than 50% of the esophageal mucosa; grade 2, more than 50% esophageal mucosa, grade 3, confluent plaque material circumferentially coating at least 50% of the mucosa without luminal impingement; grade 4, circumferential plaque mat coating at least 50% of the esophageal mucosa with luminal impingement . These patients were treated with either Nystatin 5ml QDS or fluconazole 100 mg a day orally for 5 days. As it was a case-control study a total of 153 patients fulfilled the criteria. Results: Fifty-one patients (27 male, 24 female, range 21-77 and mean age 52.9 years) fulfilled the criteria (0.34 % of the EGD). The common risk factor for candida esophagitis were carcinoma (19.6 % OR 8.05; 95% CI 1.91-47.1 and pϭ0.001), uncontrolled diabetes mellitus (27.4 % OR 7.34; 95% CI 2.26 -27.5 and pϭ0.001), corticosteroid therapy (29.4 % OR 6.67; 95% CI 2.20 -22.3 and pϭ 0.001) and antibiotics (15.6 % OR 4.56; 95% CI 1.14 -21.5 and pϭ0.02). HIV test was negative in all of these patients. The most frequent clinical symptom was retrosternal discomfort 39.3 % (20/51) and endoscopic appearance grade 2 candida esophagitis in 37.2 % (19/51). Oral candidiasis was not seen in any patient with candida esophagitis. Nystatin suspension was used in 84.3 % (43/51) and fluconazole in 15.7 % (8/51). No resistant was seen to this treatment. Conclusions: Carcinoma (esophagus, stomach, breast), diabetes mellitus, corticosteroid and antibiotic therapy are major risk factors for candida esophagitis in Pakistan. It is an easily managed complication that responds to treatment with nystatin.
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